• To offer portable diagnostic devices to every potential end-user, regardless of financial status, geographical location and training.
• Doctors, healthcare providers and patients in both the developed and developing countries will benefit equally from our technology, which intends to alleviate personal suffering and control disease outbreaks.
IRIS is a compact device for performing real-time nucleic acid amplification. IRIS was created using threedimensional (3D) additive manufacturing technology and operates via a Smartphone application.
The device can be used to extract rapidly quantitative information at a wide dynamic range of bacterial DNA, viral RNA and single point mutations. Detection can occur from genomic DNA or directly from crude samples (swabs, saliva and biopsy tissue).
•Ultra-fast detection time (5 to 20min)
•Use of crude sample (swab, saliva and biopsy tissue)
•Up to 8-sample analysis
•Smartphone application (Android, IOS)
Dr. George Papadakis
Prof. Electra Gizeli
Dr. Alexandros Pantazis
Code & Electronics Developer
Commercial & Finance
02/09/20 – BIOPIX DNA Technology P.C. receives EU funding.
BIOPIX-T (www.biopix-t.com ) is pleased to announce that a consortium of eight partners in which it participated, has been awarded EU funding (€2.4M) under the emergency call H2020-SC1-PHE-CORONAVIRUS-2020-2. The aim of the proposal, entitled “Market Release of a Portable Device for COVID-19 at the Point-of-Care; a Global Diagnostics Approach” with the acronym “IRIS-COV”, is the immediate development, certification and release of BIOPIX-T ‘s novel diagnostic platform, IRIS, to carry out a combined test for SARS-CoV–2 and Influenza A.
23/07/20 – BIOPIX DNA TECHNOLOGY P.C. won at the John and Mary Pappajohn Business Plan Competition
BIOPIX-T was one of the 5 winners, out of 138 teams that participated in the 7th John and Mary Pappajohn Business Plan Competition, organised by the Entrepreneurship Hub at Anatolia College of Thessaloniki! We would like to thank the organisers for an excellent event, despite the pandemic related constraints, and the judges for believing in our project !
20/05/20 – BIOPIX DNA TECHNOLOGY P.C. as a member at Hellenic Biocluster
BIOPIX-T is pleased to announce that it has been accepted as a member of the Hellenic Biocluster. Through the networking and collaborations that this membership will facilitate, we expect to accelerate our market entry both in Greece and abroad.
We would like to thank the management board of HBio for recognizing our technology and our commercial potential and we look forward to actively contributing to the advancement of the Biotech Sector in Greece and Europe.
12/12/19 – BIOPIX DNA TECHNOLOGY P.C. is established
We are happy to announce today the official registration of our company! BIOPIX-T aims to revolutionize molecular diagnostics at the Point-Of-Care and Home-Testing environments on a global scale.
BIOPIX DNA TECHNOLOGY P.C.
59 Therissou str., GR 71305, Heraklion, Crete, Greece
VAT no: EL 801269246 – Registry No 153132227000 – 12/12/2019